Changes in prostate cancer grading: Including a new patient-centric grading system

Prostate

Volumn 76, Issue 5, 2016, Pages 427-433

  Kryvenko, Oleksandr N ^a   Epstein, Jonathan I ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

gleason grade; gleason score; grade group; new; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GRADING; CANCER MORPHOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; COLLOID CARCINOMA; GLEASON SCORE; HUMAN; INTRADUCTAL CARCINOMA; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR DIFFERENTIATION; ADENOCARCINOMA; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84958752395     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23142     Document Type: Article

References (48)

1. Young HH, VIII,. Conservative perineal prostatectomy: The results of two years' experience and report of seventy-five cases. Ann Surg 1905; 41 (4): 549-557.
2. Young HH, XV,. Cancer of the prostate: A clinical, pathological and post-operative analysis of 111 cases. Ann Surg 1909; 50 (6): 1144-1233.
3. McNeal JE, Yemoto CE,. Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol 1996; 20 (11): 1351-1360.
4. Gleason DF,. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50 (3): 125-128.
5. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111 (1): 58-64.
6. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI,. Do adenocarcinomas of the prostate with Gleason score (GS)
7. Gleason DF,. Histological grading and staging of prostatic carcinoma. In:, Tannenbaum M, editor. Urologic pathology. Philadelphia, PA: Lea & Feibiger; 1977. pp. 171-198.
8. Epstein JI,. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 2000; 24 (4): 477-478.
9. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI,. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21 (5): 566-576.
10. Cury J, Coelho RF, Srougi M,. Well-differentiated prostate cancer in core biopsy specimens may be associated with extraprostatic disease. Sao Paulo Med J 2008; 126 (2): 119-122.
11. Fine SW, Epstein JI,. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 2008; 179 (4): 1335-1338. discussion 1338-1339.
12. Humphrey PA, Kaleem Z, Swanson PE, Vollmer RT,. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 1998; 22 (10): 1239-1246.
13. Cina SJ, Epstein JI,. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol 1997; 21 (3): 289-295.
14. Nelson RS, Epstein JI,. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol 1996; 20 (4): 419-426.
15. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL, Committee IG,. The 2005 International society of urological pathology (ISUP) Consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29 (9): 1228-1242.
16. Epstein JI, Egevad L, Amin, MB, et al., International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcino ma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2015 Oct 21. Epub ahead of print.
17. Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA,. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 2006; 68 (4): 825-830.
18. Osunkoya AO, Nielsen ME, Epstein JI,. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: A study of 47 cases. Am J Surg Pathol 2008; 32 (3): 468-472.
19. Kryvenko ON, Gupta NS, Virani N, Schultz D, Gomez J, Amin A, Lane Z, Epstein JI,. Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: Analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 2013; 137 (5): 610-617.
20. Lotan TL, Epstein JI,. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol 2009; 40 (4): 471-477.
21. Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, La Rosa FG, Cook S, Werahera PN, Lucia MS,. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 2011; 136 (1): 98-107.
22. Guo CC, Epstein JI,. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19 (12): 1528-1535.
23. Robinson B, Magi-Galluzzi C, Zhou M,. Intraductal carcinoma of the prostate. Arch Pathol Lab Med 2012; 136 (4): 418-425.
24. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME,. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: Consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med 2014; 138 (10): 1387-1405.
25. Kryvenko ON, Carter HB, Trock BJ, Epstein JI,. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014; 83 (4): 869-874.
26. Chan TY, Epstein JI,. Patient and urologist driven second opinion of prostate needle biopsies. J Urol 2005; 174 (4 Pt 1): 1390-1394. discussion 1394; author reply 1394.
27. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA,. A contemporary prostate cancer grading system: A validated alternative to the gleason score. Eur Urol 2015 Jul 9. Epub ahead of print.
28. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S,. Addressing overdiagnosis and overtreatment in cancer: A prescription for change. Lancet Oncol 2014; 15 (6): e234-e242.
29. Kryvenko ON, Epstein JI,. Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer. Pathology 2015; 47 (4): 394.
30. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S,. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013; 123 (11): 4918-4922.
31. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI,. Gleason score 6 adenocarcinoma: should it be labeled as cancer ?. J Clin Oncol 2012; 30 (35): 4294-4296.
32. Pierorazio PM, Walsh PC, Partin AW, Epstein JI,. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111 (5): 753-760.
33. Miyamoto H, Hernandez DJ, Epstein JI,. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Hum Pathol 2009; 40 (12): 1693-1698.
34. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI,. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008; 72 (1): 172-176.
35. Amin A, Partin A, Epstein JI,. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol 2011; 186 (4): 1286-1290.
36. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280 (11): 969-974.
37. Huang Y, Isharwal S, Haese A, Chun FK, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW, Veltri RW,. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. BJU Int 2011; 107 (10): 1562-1569.
38. May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O,. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol 2007; 178 (5): 1957-1962. discussion 1962.
39. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Fearn PA, Kattan MW,. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98 (10): 715-717.
40. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271 (5): 368-374.
41. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M,. 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010; 8 (2): 162-200.
42. Kryvenko ON, Balise R, Prakash NS, Epstein JI,. African American Men with Gleason Score 3+3=6 Prostate cancer produce less psa than caucasian men: A potential impact on active surveillance. J Urol 2015 Sep 2. Epub ahead of print.
43. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM,. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol 2014; 191 (1): 60-67.
44. Tsivian M, Banez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ,. African-American men with low-grade prostate cancer have higher tumor burdens: Results from the Duke Prostate Center. Prostate Cancer Prostatic Dis 2013; 16 (1): 91-94.
45. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, Stone NN,. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996; 48 (2): 234-239.
46. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL,. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190 (2): 419-426.
47. Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ,. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 2015; 28 (3): 457-464.
48. Bostrom PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR,. Genomic predictors of outcome in prostate cancer. Eur Urol 2015.